Clinical Study to Confirm MRI Safety and Effectiveness Using St. Jude Medical (SJM) Cardiac Rhythm Management Systems

Last updated: August 2, 2019
Sponsor: Abbott Medical Devices
Overall Status: Completed

Phase

N/A

Condition

Heart Disease

Fast Heart Rate (Tachycardia)

Dysrhythmia

Treatment

N/A

Clinical Study ID

NCT03012568
SJM-CIP-10137
  • All Genders

Study Summary

This is a clinical investigational plan (CIP) for the "Clinical Study to Confirm MRI Safety and Effectiveness Using SJM Cardiac Rhythm Management Systems (ASSURE MRI)". This study intends to enroll patients who meet standard bradycardia or tachycardia indications and have already been implanted with one of the SJM device/lead combinations listed in this protocol. The objective of this study is to confirm the safety and effectiveness of each of the four SJM device/lead combinations in an MRI environment. This clinical investigation is sponsored by St. Jude Medical.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Are implanted with one of the following SJM device/lead combinations evaluated in thisstudy for at least 60 days (can include patients with an eligible SJM lead for ≥ 60days OR patients with a new eligible SJM pacemaker, ImplantableCardioverter-Defibrillators (ICD), or Cardiac Resynchronization Therapy Defibrillators (CRT-D) device and eligible SJM lead implanted for at least 60 days:
  1. Accent MRI™, Assurity MRI™, Endurity MRI™, or Endurity pacemaker with Tendril™STS Model 2088 lead

  2. Accent MRI™, Assurity MRI™, Endurity MRI™, or Endurity pacemaker with IsoFlex™Optim (Model 1944 or 1948) lead

  3. Ellipse™ VR/DR or Fortify Assura VR/DR ICD with Tendril™ STS (Model 2088) orTendril MRI™ and Durata™ or Optisure™ leads

  4. Quadra Assura™ CRT-D with Tendril™ STS (Model 2088), Durata™ or Optisure™, andQuartet™ Quadripolar leads

  • Are implanted with an eligible SJM pacemaker, ICD, or CRT-D device pectorally

  • Be willing to undergo an elective MRI scan without sedation. Note: Antianxiety agents (e.g. minor tranquilizers, etc.) may be used as long as the subject can communicatewith site personnel during the MRI scan

  • Be able to provide informed consent for study participation (legal guardian is NOTacceptable)

  • Be willing and able to comply with the prescribed follow-up tests and schedule ofevaluations

Exclusion

Exclusion Criteria:

  • Have another existing active implanted medical device, e.g., neurostimulator, infusionpump, etc. that has MR labeling that will not allow the MRI scans per this protocol tobe completed.

  • Have other non-MRI compatible device or material implanted

  • NOTE: MRI compatible knee replacements, hip replacements, stents, etc. may beincluded as long as the labeling of these devices allow MRI scans conducted perthis protocol

  • NOTE: MRI compatible mechanical, prosthetic, and bioprosthetic heart valves maybe included as long as the labeling of these devices allow for MRI scansconducted per this protocol

  • NOTE: Non-removable dental implants may be included

  • Have a lead extender, adaptor, or capped/abandoned lead

  • Be unable to fit in MRI bore, i.e., subject will come into contact with the magnetfaçade inside the MRI bore.

  • Are currently participating in a clinical investigation that includes an activetreatment arm

  • Are pregnant or planning to become pregnant during the duration of the study

  • Have a life expectancy of less than 3 months due to any condition

  • Meet exclusion criteria per local law (e.g. age)

Study Design

Total Participants: 119
Study Start date:
November 10, 2016
Estimated Completion Date:
March 29, 2018

Study Description

This is a prospective, multi-center clinical study designed to confirm the safety and effectiveness of St. Jude Medical low voltage pacemakers, high voltage dual chamber Implantable Cardioverter-Defibrillators (ICD), and Cardiac Resynchronization Therapy Defibrillators (CRT-D) with various leads in an MRI environment.

The study will enroll subjects across multiple geographies and sites. Sites in geographies where MRI labelling is not yet approved may also be included after appropriate IRB/EC and local regulatory approvals, as applicable, are obtained. A prospective, multi-center study design is chosen for generalizability of study results.

The clinical study will be conducted in approximately 40 centers worldwide. Approximately 88 subjects total (with a minimum 22 subjects for each of the four device/lead combinations) will be enrolled in this study.

Enrollment in the study is expected to take approximately 6-8 months. Subjects will be followed for 1 month following the MRI scan. The total study duration of the study is expected to be 10 months, depending on the rate of enrollment.

Connect with a study center

  • Heart Care Partners - Wesley Hospital

    Auchenflower, Queensland 4066
    Australia

    Site Not Available

  • Heart Care Western Australia

    Perth, Western Australia 6000
    Australia

    Site Not Available

  • CARE Banjara

    Hyderabad, Andhra Pradesh 500034
    India

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.